Fast dissolving pharmaceutical composition

Abstract

The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises levan.

1 - 31 . (canceled) 
     
     
         32 . A pharmaceutical composition comprising:
 (a) at least one matrix-forming agent that is levan to form an open matrix network; and   (b) at least one pharmaceutically active ingredient,   
       wherein the composition is an orodispersible pharmaceutical dosage form. 
     
     
         33 . The pharmaceutical composition according to  claim 32 , further comprising one or more secondary matrix-forming agents. 
     
     
         34 . The pharmaceutical composition according to  claim 33 , wherein the one or more secondary matrix-forming agents is selected from the group consisting of trehalose, raffinose, and mannitol. 
     
     
         35 . The pharmaceutical composition according to  claim 33 , wherein the one or more secondary matrix-forming agent is mannitol. 
     
     
         36 . The pharmaceutical composition according to  claim 33 , wherein the one or more secondary matrix-forming agent is trehalose. 
     
     
         37 . The pharmaceutical composition according to  claim 33 , wherein the one or more secondary matrix-forming agent is raffinose. 
     
     
         38 . The pharmaceutical composition according to  claim 32 , wherein the at least one pharmaceutically active ingredient is chosen from desmopressin, desmopressin acetate, loratidine, famotidine, montelukast sodium, and ondansetron. 
     
     
         39 . The pharmaceutical composition according to  claim 32 , wherein at least 80% of the composition dissolves within 10 seconds upon contact with an aqueous solution or with saliva. 
     
     
         40 . The pharmaceutical composition according to  claim 32 , wherein the composition has a tensile strength from about 0.05 to about 1.6 N/mm 2 . 
     
     
         41 . A pharmaceutical composition prepared by a process comprising at least a step of sublimating a solvent from a liquid preparation that comprises:
 (a) at least one matrix-forming agent that is levan to form an open matrix network; and   (b) at least one pharmaceutically active ingredient,   
       wherein the composition is an orodispersible pharmaceutical dosage form. 
     
     
         42 . The pharmaceutical composition according to  claim 41 , wherein the liquid preparation further comprises one or more secondary matrix-forming agents. 
     
     
         43 . The pharmaceutical composition according to  claim 42 , wherein the one or more secondary matrix-forming agent is mannitol. 
     
     
         44 . The pharmaceutical composition according to  claim 42 , wherein the one or more secondary matrix-forming agent is trehalose. 
     
     
         45 . The pharmaceutical composition according to  claim 42 , wherein the one or more secondary matrix-forming agent is raffinose. 
     
     
         46 . The pharmaceutical composition according to  claim 41 , wherein the at least one pharmaceutically active ingredient is chosen from desmopressin, desmopressin acetate, loratidine, famotidine, montelukast sodium, and ondansetron. 
     
     
         47 . A blister pack having one or more depressions disposed therein, wherein each of the one or more depressions comprises a pharmaceutical composition, the composition comprising:
 (a) at least one matrix-forming agent that is levan to form an open matrix network; and   (b) at least one pharmaceutically active ingredient,   
       wherein the composition is an orodispersible pharmaceutical dosage form. 
     
     
         48 . The blister pack according to  claim 47 , which is prepared by a process comprising steps of:
 (a) introducing a liquid preparation into one or more depressions of a blister pack, the liquid preparation comprising the matrix forming agent and the pharmaceutically active ingredient; and   (b) sublimating the solvent from the liquid preparation in the one or more depressions.   
     
     
         49 . The blister pack according to  claim 47 , wherein the composition further comprises one or more secondary matrix-forming agents. 
     
     
         50 . The blister pack according to  claim 48 , wherein the one or more secondary matrix-forming agents is selected from the group consisting of trehalose, raffinose, and mannitol. 
     
     
         51 . The blister pack according to  claim 50 , wherein the one or more secondary matrix-forming agent is mannitol. 
     
     
         52 . The pharmaceutical composition according to  claim 50 , wherein the one or more secondary matrix-forming agent is trehalose. 
     
     
         53 . The pharmaceutical composition according to  claim 50 , wherein the one or more secondary matrix-forming agent is raffinose. 
     
     
         54 . The pharmaceutical composition according to  claim 47 , wherein the at least one pharmaceutically active ingredient is chosen from desmopressin, desmopressin acetate, loratidine, famotidine, montelukast sodium, and ondansetron.